ARAY vs. ANGO, ANIK, PLSE, SRDX, OFIX, CLPT, CVRX, QIPT, TELA, and DRTS
Should you be buying Accuray stock or one of its competitors? The main competitors of Accuray include AngioDynamics (ANGO), Anika Therapeutics (ANIK), Pulse Biosciences (PLSE), Surmodics (SRDX), Orthofix Medical (OFIX), ClearPoint Neuro (CLPT), CVRx (CVRX), Quipt Home Medical (QIPT), TELA Bio (TELA), and Alpha Tau Medical (DRTS). These companies are all part of the "surgical & medical instruments" industry.
AngioDynamics (NASDAQ:ANGO) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.
AngioDynamics received 30 more outperform votes than Accuray when rated by MarketBeat users. However, 65.67% of users gave Accuray an outperform vote while only 60.67% of users gave AngioDynamics an outperform vote.
AngioDynamics currently has a consensus price target of $14.25, suggesting a potential upside of 135.93%. Accuray has a consensus price target of $8.25, suggesting a potential upside of 406.13%. Given AngioDynamics' higher probable upside, analysts plainly believe Accuray is more favorable than AngioDynamics.
Accuray has a net margin of -4.99% compared to Accuray's net margin of -60.21%. Accuray's return on equity of -3.48% beat AngioDynamics' return on equity.
89.4% of AngioDynamics shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 5.1% of AngioDynamics shares are owned by company insiders. Comparatively, 3.8% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Accuray has higher revenue and earnings than AngioDynamics. Accuray is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
AngioDynamics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.
In the previous week, Accuray's average media sentiment score of 0.00 equaled AngioDynamics'average media sentiment score.
Summary
AngioDynamics beats Accuray on 8 of the 15 factors compared between the two stocks.
Get Accuray News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
